Search - tctmd.com

Displaying 1 - 20 of 109

Sort: Relevancy | Date

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Caitlin E. Cox

September 01, 2025

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

L.A. McKeown

May 16, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Daily News

Patchy Anticoagulation Use During COVID Pandemic Raises Questions

L.A. McKeown

March 06, 2025

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

L.A. McKeown

November 11, 2024

News Conference News ISET 2024

AI in Pulmonary Embolism: ‘Transformative’ for Patient Care

Caitlin E. Cox

January 30, 2024

News Conference News ISET 2024

Venous Stents: How to Choose Among the Wealth of Options

Caitlin E. Cox

January 26, 2024

News Conference News VIVA 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

L.A. McKeown

November 01, 2023

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

L.A. McKeown

August 30, 2023

News Daily News

Don’t Skimp on Anticoagulation in Isolated Distal DVT: RIDTS

Todd Neale

December 01, 2022

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

L.A. McKeown

August 30, 2022

News Daily News

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

L.A. McKeown

June 29, 2022

News Daily News

PAD Significantly Ups Morbidity and Mortality in AMICS

L.A. McKeown

March 29, 2022

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

L.A. McKeown

January 20, 2022

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

L.A. McKeown

December 21, 2021

News Daily News

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

Todd Neale

November 25, 2021

News Conference News AHA 2021

Pandemic Blamed for Loss of BP Control That Has Not Fully Rebounded

L.A. McKeown

November 18, 2021

Advertisement

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Patchy Anticoagulation Use During COVID Pandemic Raises Questions

November 2024 Dispatch for the CV Team

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

AI in Pulmonary Embolism: ‘Transformative’ for Patient Care

Venous Stents: How to Choose Among the Wealth of Options

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

October 2023 News Roundup

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

Don’t Skimp on Anticoagulation in Isolated Distal DVT: RIDTS

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

PAD Significantly Ups Morbidity and Mortality in AMICS

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

FDA Approves Two Additional Indications for Rivaroxaban in Children

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

Pandemic Blamed for Loss of BP Control That Has Not Fully Rebounded

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content